-+ 0.00%
-+ 0.00%
-+ 0.00%

Is Insmed (INSM) Still Undervalued Following Its Jefferies Conference Appearance?

Simply Wall St·11/16/2026 07:11:49
Listen to the news

Insmed (INSM) steps onto the conference circuit this month, with management scheduled to present at the Jefferies Global Healthcare Conference 2026 in London on November 16, giving investors fresh insight into this rare disease specialist.

Recent trading has been volatile for Insmed, with a 1 month share price return of 25.85% and a 7 day share price gain of 4.36% following a 1 day move of 2.62% to US$121.16. However, the year to date share price return is still down 31.59% and the 1 year total shareholder return has declined 38.62%, even after a very large 3 year total shareholder return of 3.9x that hints at momentum cooling rather than accelerating.

Scan how Insmed's recent swings compare with other rare disease and biotech opportunities by checking our curated list of 19 high quality undiscovered gems in the same broader space.

Insmed looks like a serious rare disease platform on the science side, yet the recent rebound after a tough year puts a sharper question in front of you: Does the current share price still offer enough value for that risk profile?

Most Popular Narrative: 38% Undervalued

On the analyst consensus Narrative on Simply Wall St, Insmed screens as materially undervalued, with a fair value of $196.14 against the recent $121.16 share price. This comparison puts a spotlight on how much of the rare disease plan is already priced in.

The planned growth of a global respiratory franchise built around shared pulmonology call points for BRINSUPRI, ARIKAYCE and TPIP, together with guidance for combined peak sales of more than $14b from these three assets, is intended to drive higher margin specialty pharma style earnings over time.

See why 23 investors see Insmed as 38% undervalued.

Result: Fair Value of $196.14 (UNDERVALUED)

Still, the Insmed story can change quickly if the paused broader BRINSUPRI rollout in Europe drags on, or if bronchiectasis diagnosis in comorbid COPD and asthma remains slow.

Find out about the key risks to this Insmed narrative.

Another View: What Insmed's P/S Ratio Signals

There is a catch. While the Simply Wall St cash flow model flags Insmed as undervalued overall, the current P/S ratio of 17.5x looks rich against both the US Biotechs industry at 10.2x and peers at 9.6x. It also sits above a fair ratio of 16.8x that the market could move toward.

That kind of premium suggests investors are already paying up for a lot of future execution. The real question is how comfortable you are if sentiment cools and the multiple drifts back toward that fair ratio or the wider group.

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:INSM P/S Ratio as at Nov 2026
NasdaqGS:INSM P/S Ratio as at Nov 2026

Next Steps

If this mix of enthusiasm and concern around Insmed feels familiar, consider acting while the data is fresh and reach your own conclusion by weighing the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Insmed?

You have fresh context on Insmed. Do not stop there. Broaden your watchlist now so you are not reacting late when the next move happens.